Canadian Cancer Trials Group Bulletins

General


Recent Publication

The primary results for Canadian Cancer Trials Group IND.182 (A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma) were recently published.

Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-tourah AJ, Foo AH, Walsh W, Percy ivy S, Crump M, Eisenhauer EA. Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Clinical and Pharmacodynamic Phase II Multi-Center Study of the Canadian Cancer Trials Group (ONLINE). Leuk Lymphoma 2011.

http://dx.doi.org/10.3109/10428194.2011.555892